A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses

Antonella Conforti, Daniela Peruzzi, Patrizia Giannetti, Antonella Biondo, Gennaro Ciliberto, Nicola La Monica, Luigi Aurisicchio

Research output: Contribution to journalArticle

Abstract

Human leukocyte antigen (HLA)-A2.1 transgenic mice (HHD) represent a valuable model to study and predict the immunogenicity of vaccines against pathogens. However, HHD mice are unsuitable for in vivo studies of cancer vaccines against human tumor-associated antigens because they lack T-cell tolerance that is key to define the potency of the treatment. In this study, we developed HHD/carcinoembryonic antigen P(CEA) hybrid mice by breeding transgenic mice homozygous for CEA with HHD. These mice express human CEA, present epitopes solely through HLA-A2.1 molecules and constitute a unique in vivo animal model to study HLA-A2.1-restricted immune response of a human CEA-based vaccine. Owing to the immune tolerance, HHD/CEA mice show a limited immune response and expansion of a different and restricted T-cell receptor repertoire after antigen-specific stimulation. Our data show that genetic vectors expressing CEA and peptide-based vaccines are able to efficiently break immune tolerance against CEA and to elicit strong immune response against HLA-A2.1-restricted CEA epitopes. Most importantly, efficient lysis of human CEA/HLA-A2.1 tumor cells was observed and significant protection against HHD/CEA tumor cells was achieved in HHD/CEA-vaccinated mice. Hence, HHD/CEA provides a relevant model for the evaluation of the potential efficacy of human CEA-based vaccines.

Original languageEnglish
Pages (from-to)744-754
Number of pages11
JournalJournal of Immunotherapy
Volume32
Issue number7
DOIs
Publication statusPublished - Sep 2009

Fingerprint

Cancer Vaccines
Carcinoembryonic Antigen
HLA Antigens
varespladib methyl
Immune Tolerance
Transgenic Mice
Epitopes
Vaccines
Genetic Vectors
Subunit Vaccines
Neoplasm Antigens
T-Cell Antigen Receptor
Breeding
Neoplasms

Keywords

  • Cancer vaccine
  • CEA
  • HLA-A2.1
  • Tolerance

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Cancer Research
  • Pharmacology

Cite this

A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses. / Conforti, Antonella; Peruzzi, Daniela; Giannetti, Patrizia; Biondo, Antonella; Ciliberto, Gennaro; Monica, Nicola La; Aurisicchio, Luigi.

In: Journal of Immunotherapy, Vol. 32, No. 7, 09.2009, p. 744-754.

Research output: Contribution to journalArticle

Conforti, Antonella ; Peruzzi, Daniela ; Giannetti, Patrizia ; Biondo, Antonella ; Ciliberto, Gennaro ; Monica, Nicola La ; Aurisicchio, Luigi. / A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses. In: Journal of Immunotherapy. 2009 ; Vol. 32, No. 7. pp. 744-754.
@article{112b94ef56d24522b2c9cf70f9be39f9,
title = "A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses",
abstract = "Human leukocyte antigen (HLA)-A2.1 transgenic mice (HHD) represent a valuable model to study and predict the immunogenicity of vaccines against pathogens. However, HHD mice are unsuitable for in vivo studies of cancer vaccines against human tumor-associated antigens because they lack T-cell tolerance that is key to define the potency of the treatment. In this study, we developed HHD/carcinoembryonic antigen P(CEA) hybrid mice by breeding transgenic mice homozygous for CEA with HHD. These mice express human CEA, present epitopes solely through HLA-A2.1 molecules and constitute a unique in vivo animal model to study HLA-A2.1-restricted immune response of a human CEA-based vaccine. Owing to the immune tolerance, HHD/CEA mice show a limited immune response and expansion of a different and restricted T-cell receptor repertoire after antigen-specific stimulation. Our data show that genetic vectors expressing CEA and peptide-based vaccines are able to efficiently break immune tolerance against CEA and to elicit strong immune response against HLA-A2.1-restricted CEA epitopes. Most importantly, efficient lysis of human CEA/HLA-A2.1 tumor cells was observed and significant protection against HHD/CEA tumor cells was achieved in HHD/CEA-vaccinated mice. Hence, HHD/CEA provides a relevant model for the evaluation of the potential efficacy of human CEA-based vaccines.",
keywords = "Cancer vaccine, CEA, HLA-A2.1, Tolerance",
author = "Antonella Conforti and Daniela Peruzzi and Patrizia Giannetti and Antonella Biondo and Gennaro Ciliberto and Monica, {Nicola La} and Luigi Aurisicchio",
year = "2009",
month = "9",
doi = "10.1097/CJI.0b013e3181aee1b6",
language = "English",
volume = "32",
pages = "744--754",
journal = "Journal of Immunotherapy",
issn = "1053-8550",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses

AU - Conforti, Antonella

AU - Peruzzi, Daniela

AU - Giannetti, Patrizia

AU - Biondo, Antonella

AU - Ciliberto, Gennaro

AU - Monica, Nicola La

AU - Aurisicchio, Luigi

PY - 2009/9

Y1 - 2009/9

N2 - Human leukocyte antigen (HLA)-A2.1 transgenic mice (HHD) represent a valuable model to study and predict the immunogenicity of vaccines against pathogens. However, HHD mice are unsuitable for in vivo studies of cancer vaccines against human tumor-associated antigens because they lack T-cell tolerance that is key to define the potency of the treatment. In this study, we developed HHD/carcinoembryonic antigen P(CEA) hybrid mice by breeding transgenic mice homozygous for CEA with HHD. These mice express human CEA, present epitopes solely through HLA-A2.1 molecules and constitute a unique in vivo animal model to study HLA-A2.1-restricted immune response of a human CEA-based vaccine. Owing to the immune tolerance, HHD/CEA mice show a limited immune response and expansion of a different and restricted T-cell receptor repertoire after antigen-specific stimulation. Our data show that genetic vectors expressing CEA and peptide-based vaccines are able to efficiently break immune tolerance against CEA and to elicit strong immune response against HLA-A2.1-restricted CEA epitopes. Most importantly, efficient lysis of human CEA/HLA-A2.1 tumor cells was observed and significant protection against HHD/CEA tumor cells was achieved in HHD/CEA-vaccinated mice. Hence, HHD/CEA provides a relevant model for the evaluation of the potential efficacy of human CEA-based vaccines.

AB - Human leukocyte antigen (HLA)-A2.1 transgenic mice (HHD) represent a valuable model to study and predict the immunogenicity of vaccines against pathogens. However, HHD mice are unsuitable for in vivo studies of cancer vaccines against human tumor-associated antigens because they lack T-cell tolerance that is key to define the potency of the treatment. In this study, we developed HHD/carcinoembryonic antigen P(CEA) hybrid mice by breeding transgenic mice homozygous for CEA with HHD. These mice express human CEA, present epitopes solely through HLA-A2.1 molecules and constitute a unique in vivo animal model to study HLA-A2.1-restricted immune response of a human CEA-based vaccine. Owing to the immune tolerance, HHD/CEA mice show a limited immune response and expansion of a different and restricted T-cell receptor repertoire after antigen-specific stimulation. Our data show that genetic vectors expressing CEA and peptide-based vaccines are able to efficiently break immune tolerance against CEA and to elicit strong immune response against HLA-A2.1-restricted CEA epitopes. Most importantly, efficient lysis of human CEA/HLA-A2.1 tumor cells was observed and significant protection against HHD/CEA tumor cells was achieved in HHD/CEA-vaccinated mice. Hence, HHD/CEA provides a relevant model for the evaluation of the potential efficacy of human CEA-based vaccines.

KW - Cancer vaccine

KW - CEA

KW - HLA-A2.1

KW - Tolerance

UR - http://www.scopus.com/inward/record.url?scp=68449088812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68449088812&partnerID=8YFLogxK

U2 - 10.1097/CJI.0b013e3181aee1b6

DO - 10.1097/CJI.0b013e3181aee1b6

M3 - Article

C2 - 19561534

AN - SCOPUS:68449088812

VL - 32

SP - 744

EP - 754

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1053-8550

IS - 7

ER -